GleamWall
中文EN

INAB IN8BIO, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1740279 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY6.1%
TTM EPS YoY80.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-141.8%
ROA-109.4%
ROIC (approx.)-1,362.1%
Asset turnover—

Leverage & solvency

Liabilities / assets24.2%
Debt / equity0.00x
Current ratio5.78x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-26.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$10.21M$16.96M
SG&A expense$9.65M$12.64M
Operating income-$19.44M-$30.44M
Pretax income-$19.44M-$30.68M
Income tax$0$0
Net income-$19.44M-$30.44M
EBITDA-$18.44M-$29.46M
EPS (basic)-4.44-17.05
EPS (diluted)-4.44-17.05
Weighted avg. shares (diluted)4.37M1.78M
Balance sheet
Cash & equivalents$27.31M$11.39M
Current assets$27.88M$12.58M
PP&E, net$1.86M$2.86M
Total assets$32.28M$20.94M
Current liabilities$3.16M$3.08M
Total liabilities$4.72M$6.47M
Shareholders' equity$27.56M$14.48M
Shares outstanding9.77M2.42M
Cash flow statement
Operating cash flow-$12.71M-$24.15M
Investing cash flow$0-$187,000
Financing cash flow$28.64M$14.18M
Depreciation & amortization$1.00M$976,000
Stock-based compensation$3.19M$5.00M

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.